Osteoarthritis

Effect of intra-knee injection of autologous adipose stem cells or mesenchymal vascular components on short-term outcomes in patients with knee osteoarthritis: an updated meta-analysis of randomized controlled trials

Arthritis Res TherPublished Systematic review and meta-analysis of randomised trials

Authors' conclusion

In conclusion, in osteoarthritis of the knee, single or multiple intra-articular injections of autologous ASCs or ADSVF have shown significant pain improvement and safety in the short term in the absence of adjuvant therapy. Significant improvements in cartilage status were also shown.

Study context

Population
Patients with knee osteoarthritis (OA)7 randomized controlled trials (RCTs)
Comparison
Single or multiple intra-articular injections of autologous ASCs or adipose-derived stromal vascular fraction (ADSVF) vs placebo or hyaluronic acid
Outcome
Pain relief
Follow-up
Short term

Pooled result

As reported in the abstract

Z

3.10

P < 0.0001

Single injection ASCs or ADSVF

Z

4.66

P < 0.00001

Multiple injections ASCs or ADSVF

Further pooled results

OutcomeZP value
Function, short termSingle injection ASCs or ADSVF vs Control2.61P < 0.009
Function, short termMultiple injections ASCs or ADSVF vs Control2.80P = 0.005

Cartilage condition on MRI

Cartilage condition on MRI, first of two analyses
Z = 8.14; P < 0.000001
Cartilage condition on MRI, second of two analyses
Z = 5.58; P < 0.00001
Significant improvement in cartilage condition vs control on MRI
  • The abstract does not state which of the two analyses is single and which is multiple injection

Original publication

Effect of intra-knee injection of autologous adipose stem cells or mesenchymal vascular components on short-term outcomes in patients with knee osteoarthritis: an updated meta-analysis of randomized controlled trials. Arthritis Res Ther. Published 10 August 2023. doi:10.1186/s13075-023-03134-3

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.